关于这一集
In this episode of Cracking Cancer, host Rob Swanda, PhD, is joined by thoracic medical oncologist Dr. Mark Jeng (Memorial Sloan Kettering Cancer Center) and patient advocate Loryn Fatus, who was diagnosed with Stage IV HER2-mutant non-small cell lung cancer at age 34. Loryn shares her challenging path to diagnosis as a young, healthy non-smoker, detailing how nonspecific symptoms—like persistent back pain, extreme fatigue, and small ground-glass lung nodules—were initially attributed to pneumonia, post-surgical gallbladder recovery, and suspected rheumatological issues before a broken rib and liver/bone metastases revealed lung cancer.
Dr. Jeng breaks down the biology of HER2 alterations in lung cancer, introducing the "HER2 Triad" (mutation, protein overexpression, and gene amplification) and explaining why each requires distinct diagnostic testing (liquid/tissue NGS vs. IHC staining). The panel also explores the evolution of HER2-directed therapies—from Loryn’s 19-month run on the antibody-drug conjugate trastuzumab deruxtecan (Enhertu / T-DXd) to her recent transition onto an oral tyrosine kinase inhibitor (zongertinib). Together, they highlight how personalized dosing schedules, palliative care integration, and proactive patient advocacy are turning Stage IV lung cancer into a manageable, chronic condition.
Key Takeaways:
- Lung Cancer in Non-Smokers & Young Adults
- The "HER2 Triad" Requires Distinct Testing
- How Antibody-Drug Conjugates (ADCs) Work
- Dosing Adjustments Protect Quality of Life
- Strategic Treatment Sequencing & Oligoprogression
Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast)
Chapters:
0:00 Welcome & Introductions: Loryn Fatus and Dr. Mark Chang
2:15 Loryn’s Story: Nonspecific Symptoms, Ground-Glass Nodules, and a Delayed Diagnosis
7:40 Dispelling Myths: Lung Cancer in Non-Smokers and Somatic vs. Inherited Mutations
12:15 The HER2 Triad: Mutation vs. Overexpression vs. Amplification
17:50 Anatomy of an ADC: How Enhertu Acts as a "Trojan Horse"
23:10 Managing ADC Side Effects & Monitoring for Interstitial Lung Disease (ILD)
29:45 Redefining Stage IV: Functional Cures, Chronic Management, and ASCO Milestones
35:20 Quality of Life Adjustments: Shifting to 4-Week Infusions and Palliative Care
41:10 Oligoprogression and Transitioning to Oral TKIs (Zongertinib)
46:30 Closing Takeaways: Advocating for Reflex Testing and Patient Empowerment
To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org
Attributions
The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License
X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X
IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos